Grace Therapeutics (GRCE) Intangibles (2019 - 2026)

Grace Therapeutics has disclosed Intangibles across 8 years of filings, most recently posting $27.6 million for Q2 2026.

• In Q2 2026, Intangibles fell 32.9% year-over-year to $27.6 million; the TTM figure through Jun 2026 stood at $27.6 million (down 32.9% YoY), while the FY2026 annual figure was $41.1 million, changed 0.0% from the prior year.
• Intangibles came in at $27.6 million for Q2 2026 at Grace Therapeutics, down from $41.1 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $69.8 million in Q1 2022 to a low of $27.6 million in Q2 2026.
• Average Intangibles over 5 years is $46.7 million, with a median of $41.1 million recorded in 2023.
• Year-over-year, Intangibles rose 7.06% in 2022 and plunged 41.09% in 2023.
• Over 5 years, Intangibles stood at $69.8 million in 2022, then sank by 41.09% to $41.1 million in 2023, then changed by 0.0% to $41.1 million in 2024, then changed by 0.0% to $41.1 million in 2025, then tumbled by 32.9% to $27.6 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $27.6 million in Q2 2026, $41.1 million in Q1 2026, and $41.1 million in Q4 2025.